Updated: Verve's landmark base editing trial for cardio drug runs into FDA hold
Four months after kicking off the first-ever base editing trial in humans, Verve Therapeutics is running up against a regulatory wall.
The FDA placed Verve’s lead program, VERVE-101, on hold early Monday morning, pausing the biotech’s US efforts following an IND submission last month. Verve kicked off the Phase Ib trial this past summer, dosing three patients in New Zealand and the UK starting in July.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.